AU2021255559A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
AU2021255559A1
AU2021255559A1 AU2021255559A AU2021255559A AU2021255559A1 AU 2021255559 A1 AU2021255559 A1 AU 2021255559A1 AU 2021255559 A AU2021255559 A AU 2021255559A AU 2021255559 A AU2021255559 A AU 2021255559A AU 2021255559 A1 AU2021255559 A1 AU 2021255559A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
total weight
amount
api
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021255559A
Other languages
English (en)
Inventor
Shun Chen
Peter Farina
Zeren Wang
Jun Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Pharmacin Co Ltd
Original Assignee
Shenzhen Pharmacin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Pharmacin Co Ltd filed Critical Shenzhen Pharmacin Co Ltd
Publication of AU2021255559A1 publication Critical patent/AU2021255559A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021255559A 2020-04-17 2021-04-16 Pharmaceutical compositions Abandoned AU2021255559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/085241 2020-04-17
CN2020085241 2020-04-17
PCT/CN2021/087690 WO2021209025A1 (en) 2020-04-17 2021-04-16 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AU2021255559A1 true AU2021255559A1 (en) 2022-11-17

Family

ID=78084668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021255559A Abandoned AU2021255559A1 (en) 2020-04-17 2021-04-16 Pharmaceutical compositions

Country Status (8)

Country Link
US (1) US20230128252A1 (https=)
EP (1) EP4135699A4 (https=)
JP (1) JP2023522065A (https=)
KR (1) KR20230004644A (https=)
CN (1) CN115135323A (https=)
AU (1) AU2021255559A1 (https=)
CA (1) CA3180160A1 (https=)
WO (1) WO2021209025A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
CN116115563B (zh) * 2023-03-30 2023-08-29 石家庄四药有限公司 一种氟比洛芬混悬注射液及其制备方法
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions
CN117731649B (zh) * 2023-12-21 2025-01-28 博济医药科技股份有限公司 一种氨甲环酸药物组合物及其制备工艺
CN119837856A (zh) * 2024-12-11 2025-04-18 江南大学 一种具有预防和改善特应性皮炎的黄酮组合物及其应用
CN120865107B (zh) * 2025-09-22 2026-01-23 中国医学科学院医药生物技术研究所 一种苯吩嗪衍生物、其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814814C2 (de) * 1998-04-02 2002-01-31 Gerhard Steffan Wasserlösliche, Iminophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US10179159B2 (en) * 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
CA2775393C (en) * 2012-05-02 2014-04-29 Samy Saad Topical non-aqueous pharmaceutical formulations
US8852648B2 (en) * 2012-11-06 2014-10-07 Rochal Industries, Llp Delivery of biologically-active agents using volatile, hydrophobic solvents
CN105492004A (zh) * 2013-02-08 2016-04-13 罗达制药有限公司 治疗局部微生物感染的方法
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CN105693668A (zh) * 2016-04-23 2016-06-22 贺玉皓 一种氯法齐明的药物组合物及其医药用途

Also Published As

Publication number Publication date
WO2021209025A1 (en) 2021-10-21
JP2023522065A (ja) 2023-05-26
US20230128252A1 (en) 2023-04-27
EP4135699A4 (en) 2024-05-01
EP4135699A1 (en) 2023-02-22
KR20230004644A (ko) 2023-01-06
CA3180160A1 (en) 2021-10-21
CN115135323A (zh) 2022-09-30

Similar Documents

Publication Publication Date Title
US20230128252A1 (en) Pharmaceutical compositions
JP7744166B2 (ja) ステロイドの抗痙攣活性
US20240261278A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
CN104902875B (zh) 四环素局部制剂、其制备及用途
US20030118528A1 (en) Topical delivery of codrugs
KR20180080189A (ko) 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
JP2005518354A5 (https=)
US20240245713A1 (en) Long-acting injectable formulations and use thereof
US20210361771A1 (en) Terpene coupling conjugate
AU2009273211B2 (en) Transdermal pharmaceutical compositions comprising danazol
TWI729371B (zh) 治療搔癢症的組合物與方法
US20050158371A1 (en) Novel external agent
CN115279788A (zh) 用于治疗银屑病和其他疾病的外用环孢霉素
Singh Development and evaluation of ketoprofen solid dispersion incorporated topical gels
WO2001013938A1 (fr) Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period